Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence? by Gil-Bazo, I. (Ignacio) et al.
• LETTERS TO THE EDITOR  •
Role of von Willebrand factor levels in the prognosis of stage IV
colorectal cancer: Do we have enough evidence?
I. Gil-Bazo, J. A Díaz-González, J. Rodríguez, J. Cortés, E. Calvo, J. A. Páramo, J. García-Foncillas
ELSEVIER
PO Box 2345, Beijing 100023, China                                                                                                                                                          World J Gastroenterol  2005;11(38):6072-6073
www.wjgnet.com                                                                                                     
                                
         World Journal of Gastroenterology  ISSN 1007-9327
wjg@wjgnet.com                                                                                                                                                                                       © 2005 The WJG Press and Elsevier Inc. All rights reserved.
I. Gil-Bazo, J.A Díaz-González, J. García-Foncillas, Department
of Oncology, University Clinic, University of Navarra, Pío XII, 36.
31008 Pamplona, Spain
 J.A. Páramo, Service of Haematology, University Clinic, University
of Navarra, Pío XII, 36. 31008 Pamplona, Spain
J. Cortés, Department of Oncology, Vall d’Hebron, University
Hospital,  Pg Vall d’Hebron, 119-129, E-08035 Barcelona, Spain
E. Calvo, Institute for Drug Development, Cancer Therapy and
Research Center. University of Texas Health Science Center at San
Antonio,  7979 Wurzbach Road, Zeller Building, San Antonio, TX
78229, United States
Correspondence to: I. Gil-Bazo, MD, PhD, Cancer Biology and
Genetics Program, Memorial Sloan-Kettering Cancer Center, 1275
York Avenue, Box 241, New York, NY 10021,
United States.  gilbazoi@mskcc.org
Telephone: +1-21-26392390    Fax: +1-646-4222063
Received: 2005-04-30    Accepted: 2005-06-09
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
Key words: Von Willebrand factor; Colorectal cancer;
Prognosis
Gil-Bazo I, Díaz-González JA, Rodríguez J, Cortés J, Calvo E,
Páramo JA, García-Foncillas J. Role of von Willebrand factor
levels in the prognosis of stage IV colorectal cancer: Do we




Cancer patients usually present a prothrombotic condition.
Several clotting-related proteins, such as von Willebrand
factor (vWF), presenting higher plasma concentrations in
these patients, may play a key role in this process. Moreover,
some of those proteins are currently being characterized as
response rate and overall survival markers in metastatic
colorectal cancer (MCRC). In this comment article, we
discuss the last piece of evidence that supports the use of
vWF as a prognostic indicator in MCRC patients, provided
by a paper recently published by Wang et al., in the World
Journal of  Gastroenterology. Summarizing, although vWF
should be seriously considered as potential future prognostic
and predictive indicator in colorectal cancer, more dynamic
and better designed studies in longer series of patients should
be conducted before standardizing its universal use among
these patients.
Wang et al.[1], have recently published an encouraging
paper in the World Journal of  Gastroenterology regarding
the possible and novel use, as a prognostic factor, of
vWF plasma levels in MCRC.
As the authors expose, cancer patients often show an
imbalance between coagulation and fibrinolysis systems,
which results in their prothrombotic condition[2-6]. Several
clotting-related proteins, such as vWF, presenting higher
plasma concentrations in these patients[7-11], may play a key
role in this process. Moreover, some of those proteins are
currently being characterized as response rate and overall
survival markers in MCRC[12-16].
Accordingly, the data shown by Wang et al.[1], seem to
indicate that plasma vWF concentrations are increased among
colorectal cancer patients and correlate with tumor stage.
In addition, those vWF higher levels may be related to
significantly poor prognosis of subjects presenting metastasis.
However, although authors are aware of the important
variability of vWF levels in humans due to the presence of
a variety of diseases like diabetes mellitus, connective tissue
disease, cardiovascular dysfunctions, thrombo-embolic
events, acute infections, and other conditions like age or
gender[17-20], patients suffering any of those illnesses were
not apparently excluded from the study nor controlled by
those factors in the multivariate analysis.
More strikingly, even though platelets are partially
responsible for vascular endothelial growth factor (VEGF)
levels[21-25], and VEGF is considered the most potent activator
of the endothelium (main vWF producer), neither platelet
count nor VEGF levels were measured and included in the
statistical analysis.
Other issue that remains unclear in this article is whether
the chemotherapy (CMT) regime used (5-fluorouracil alone
or in combination with irinotecan, oxaliplatin or capecitabine)
in each group of patients could have accounted for the
differences observed between the survival curves for
individuals presenting vWF¡Ý160% and those with levels
below that threshold. Thus, in order to avoid the possible
bias, the CMT regime administered to each patient should
have also been taken into account in the multivariate
statistical analysis.
Finally, given the fact that the CMT could catalyze the
original risk for progression and death in these patients
due to its alleged antiangiogenic effect, measuring vWF
concentrations during treatment may modify the prognostic
value of this protein.
According to this, in the University Clinic of the
University of Navarra, 64 colorectal cancer patients were
enrolled from 2002 and 2004. Blood samples were taken
dynamically before and after fluoropirimidine-based CMT
in 32 patients presenting metastasis, and stored until further
processing. vWF, VEGF, plasminogen activator inhibitor
(PAI) 1, D-dimer, fibrinogen levels and platelet count were
measured before and after CMT using standardized
techniques. Gender, age, ECOG performance status, tumor
burden, CMT course, and regime and CEA/CA 19.9 levels
were also considered for the statistical analysis. Patients
received a median of 3 cycles of CMT (range: 2-10) between
both blood samples. After a median follow-up of 10 mo,
baseline levels of vWF >202% showed an associated hazard
ratio (HR), for death higher than patients with vWF ¡Ü202%,
with tendency to the statistical significance (P = 0.08).
Meanwhile, post-CMT vWF levels above 189% were related
to a fourfold HR for progression with respect to those
subjects showing concentrations ¡Ü189% after CMT
treatment. These results were adjusted for the rest of the
different protein levels measured, age, gender, ECOG
performance status, tumor burden, and CMT course and
regime.
In conclusion, although vWF and other coagulation/
fibrinolysis factors should be seriously considered as
potential future prognostic and predictive indicators in
colorectal cancer, more dynamic and better designed studies
in longer series of patients should be conducted before
standardizing their universal use among these patients.
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